Intra-Cellular Therapies, Inc.

210 articles about Intra-Cellular Therapies, Inc.

• Intra-Cellular Therapies Prices Public Offering of Common Stock

  9/10/2020

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 11,666,667 shares of its common stock at a public offering price of $30.00 per share

• Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock - Sep 09, 2020

  9/9/2020

  Intra-Cellular Therapies, Inc., a biopharmaceutical company, announced that it has commenced an underwritten public offering of $350 million of shares of its common stock.

• Intra-Cellular Therapies Announces Positive Topline Results from Study 402 Evaluating Lumateperone as Adjunctive Therapy in Patients with Bipolar Depression

  9/9/2020

  Lumateperone 42 mg achieved statistically significant results in primary and key secondary endpoints in Study 402. Company expects to submit supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) in late 2020 or early 2021.

• Intra-Cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  8/10/2020

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the second quarter ended June 30, 2020, and provided a corporate update. “We have completed our first full quarter of commercial activities, adapting to the unprecedented challenges of the COVID-19 pandemic, and I am encouraged

• Intra-Cellular Therapies to Host Second Quarter 2020 Financial Results Conference Call and Webcast

  8/4/2020

  Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Monday, August 10, 2020, to provide a corporate update and discuss details of the Company's financial results for the quarter ended June 30, 2020. To access

• Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I/II Study in Patients with Heart Failure

  6/29/2020

  Study demonstrated inhibiting phosphodiesterase-1 with ITI-214 in patients with heart failure improved cardiac function by enhancing cardiac contractility and dilating systemic arteries without inducing abnormal heart rhythms.

• Intra-Cellular Therapies to Present at the 2020 RBC Capital Markets Global Healthcare Conference

  5/14/2020

  Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 2020 RBC Capital Markets Global Healthcare Conference

• Intra-Cellular Therapies to Host Virtual Annual Meeting of Stockholders

  5/13/2020

  Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will hold its 2020 Annual Meeting of Stockholders

• Intra-Cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update

  5/7/2020

  Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced its financial results for the first quarter ended March 31, 2020, and provided a corporate update.

• Intra-Cellular Therapies to Host First Quarter 2020 Financial Results Conference Call and Webcast

  4/29/2020

  Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, May 7, 2020, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2020. To access

• Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  4/16/2020

  Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the grant to 266 new employees of inducement stock options to purchase an aggregate of 33,040 shares of its common stock and restricted stock units for an aggregate of 267,729 shares of its common stock under its 2019 Inducement Award Plan. The stock opt

• Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in AdultsIntra-Cellular Therapies launches LYTAlink™, a comprehensive patient affordability and access program for CAPLYTA

  4/2/2020

  Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced it has successfully initiated its promotional activities associated with the launch of CAPLYTA.

• Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia

  3/23/2020

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA (lumateperone) is now available to pharmacies in the U.S

• Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update

  3/2/2020

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ending December 31, 2019, and provided a corporate update.

• Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast

  2/24/2020

  Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Monday, March 2, 2020, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2019.

• Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb. 21, 2020

  2/21/2020

  Intra-Cellular Therapies, Inc. announced the grant to four new employees of inducement stock options to purchase an aggregate of 6,688 shares of its common stock and restricted stock units for an aggregate of 6,681 shares of its common stock under its 2019 Inducement Award Plan.

• Pivotal Study of CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults Published in JAMA Psychiatry

  2/20/2020

  NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced the publication of results from its CAPLYTA (lumateperone) clinical trial (ITI-007-301) in adult patients with schizophrenia. The article, "Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial" (Correll et al. 2020), w

• Intra-Cellular Therapies to Present at the 9th Annual SVB Leerink Global Healthcare Conference

  2/18/2020

  Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 9th Annual SVB Leerink Global Healthcare Conference in New York

• Intra-Cellular Therapies Prices Public Offering of Common Stock at $29.50 per share

  1/8/2020

  Intra-Cellular Therapies, Inc. announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $29.50 per share.

• Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock - Jan. 06, 2020

  1/6/2020

  Intra-Cellular Therapies, Inc., a biopharmaceutical company, announced that it has commenced an underwritten public offering of 10,000,000 shares of its common stock.